AWM Investment Company Inc. Makes New Investment in OPKO Health, Inc. $OPK
AWM Investment Company Inc. recently acquired a new stake of 2,110,000 shares in OPKO Health, Inc. (NASDAQ:OPK), valued at approximately $3,165,000. This investment makes AWM Investment Company Inc. an owner of about 0.28% of OPKO Health. Other institutional investors also made new investments in OPKO Health, and the company has received a consensus "Hold" rating from analysts with a target price of $1.55.
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know
OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movements. The Zacks Rank system, which uses earnings estimate revisions, aims to identify stocks with the potential for market-beating returns.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health, Inc. (OPK) shares have risen 12.4% in the last month, driven by narrower operating losses, improved margins, and favorable estimate revisions. While the company remains unprofitable, its future upside depends on clinical pipeline execution and progress at BioReference. Despite a mixed broader outlook, OPK's recent momentum is supported by its strong Momentum Score, though other style scores are less favorable.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health (OPK) has secured an additional $125 million in financing by leveraging future royalties from its mazdutide license agreement with Eli Lilly and Company (LLY). This non-dilutive funding, structured as senior secured notes maturing in 2044, provides capital for OPK's extensive clinical pipeline and operating needs without issuing new equity. While it offers immediate liquidity, the company retains exposure to future royalty growth in China, but still faces execution risks associated with its pipeline and diagnostics business.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health (OPK) shares have risen 12.4% over the past month, driven by narrower operating losses, improved margins, and favorable estimate revisions. While the company remains loss-making, its BioReference division has turned profitable, and pharmaceutical revenues have significantly increased. Upcoming clinical milestones for ModeX and other candidates in late 2026 or early 2027 could further support the stock, though profitability and execution risks remain.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health (OPK) secured an additional $125 million in non-dilutive financing against royalties from its mazdutide license agreement with Eli Lilly and Company. This funding, from HealthCare Royalty, a KKR business, provides capital without issuing common shares and helps support OPK's broad clinical pipeline, including various R&D programs. While enhancing financial flexibility, the article notes that execution risks remain for OPK's pipeline and diagnostics business, despite an improved Momentum Score.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPKO Health has secured an additional $125 million in financing from HealthCare Royalty (HCRx) by leveraging its royalty interests from the mazdutide license agreement with Eli Lilly. This non-dilutive capital injection aims to enhance OPKO's financial flexibility and liquidity, allowing it to fund operations and advance its pipeline while retaining long-term upside in mazdutide royalties after a 1.5x cap on funded payments. The deal underscores the value of OPKO's royalty portfolio, particularly mazdutide's growth potential in China, and follows a strong Q2 2026 performance with narrower losses and increased revenues.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPKO Health has secured an additional $125 million in financing from HealthCare Royalty (HCRx) by issuing senior secured notes backed by future royalties from its mazdutide licensing agreement with Eli Lilly. This non-dilutive capital injection allows OPKO to strengthen its financial flexibility and fund operations, while retaining long-term participation in mazdutide's royalty potential after payments reach 1.5 times the funded amount. The financing highlights the attractiveness of OPKO's royalty assets, especially given mazdutide's growth prospects in the Chinese market.
Should OPKO Health’s Royalty-Backed US$125 Million Financing Shift Matter to OPKO Health (OPK) Investors?
OPKO Health recently secured a US$125 million royalty-backed financing deal, converting future mazdutide license royalties into immediate non-dilutive capital with a 1.5-times cap on total payments. This financing aims to boost near-term liquidity without share dilution, but the company still faces significant challenges from persistent losses and increasing competition in GLP-1 and diagnostics markets. Investors are left to weigh whether existing products and partnerships can sufficiently narrow losses to justify increased debt and ongoing share buybacks.
OPKO Health (OPK) Raises $125 Million, Is The Upside Already Priced In?
OPKO Health (OPK) secured an additional $125 million in senior secured notes from HealthCare Royalty, linked to mazdutide royalties, providing non-dilutive capital. While recent share price performance shows near-term momentum, its 5-year total shareholder return has declined significantly. The article discusses two contrasting views on OPKO's valuation: a "most popular narrative" suggesting it is 68.5% undervalued with a fair value of $4.38 based on future growth and partnerships, and "another view" highlighting current overvaluation based on P/S ratio compared to the industry and its fair ratio.
OPKO Health Raises $125 Million in Additional Royalty-Backed Notes Under Amended HCR Agreement
OPKO Health has secured an additional $125 million in senior secured notes by amending its 2024 Note Purchase Agreement with HCR Injection SPV to enhance liquidity. These royalty-backed notes mature in 2044 and bear interest based on 3-month SOFR plus 7.5%, with payments primarily sourced from EirGen's profit share from Pfizer and secondarily from mazdutide sales royalties. The agreement details include guarantees from OPKO subsidiaries and security through related royalty and profit share streams.
OPKO Health (NASDAQ:OPK) Trading Down 5.4% - Here's What Happened
OPKO Health (NASDAQ:OPK) shares experienced a 5.4% drop in mid-day trading, closing at $1.325 with significantly lower trading volume than average. Despite the stock decline, the company recently reported better-than-expected quarterly earnings, with an adjusted loss of $0.01 per share against an anticipated $0.08 loss, and revenue of $163.58 million, surpassing analyst estimates. Analysts currently maintain a "Hold" consensus rating for OPKO Health, with an average price target of $1.55.
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Analysts
OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $1.55. Recent analyst actions include upgrades from Weiss Ratings and Wall Street Zen, a downgrade from Barrington Research, and a reissued "buy" rating from HC Wainwright. The company recently reported Q2 earnings of ($0.01) per share, beating consensus estimates, and saw its revenue increase by 4.3% year-over-year.
OPKO Health, Inc. announced that it has received $375 million in funding from Healthcare Royalty Management, LLC
OPKO Health, Inc. has secured $375 million in funding from Healthcare Royalty Management, LLC. This includes an additional $125 million notes issuance on August 13, 2026, building on a previous strategic relationship. These notes mature in 2044 and bear interest at a variable rate with a 4.0% per annum floor, secured by royalty payments from Mazdutide.
OPKO Health, Inc. Expands Strategic Relationship with Healthcare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health, Inc. has expanded its financing relationship with HealthCare Royalty (a KKR business) by issuing an additional $125 million in senior secured notes. These notes are backed by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company, maturing in 2044. This transaction provides OPKO with non-dilutive capital, enabling it to access immediate value from an emerging royalty stream while retaining significant long-term participation in the mazdutide franchise.
OPKO Health secures $125m financing backed by mazdutide royalties
OPKO Health Inc. has secured $125 million in senior secured notes through an expanded financing agreement with HealthCare Royalty, a business of KKR. This financing is backed by OPKO’s royalty interests from its mazdutide license agreement with Eli Lilly and Company, with notes maturing in 2044. Mazdutide is commercialized in China by Innovent Biologics, and OPKO began receiving royalties in 2025.
OPKO Health raises $125M in notes backed by mazdutide royalties
OPKO Health (NASDAQ: OPK) has secured $125 million in senior secured notes from HealthCare Royalty, a KKR business. These notes are backed by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company and mature in 2044. This financing arrangement is described as non-dilutive, allowing OPKO to retain future royalty economics after total payments reach 1.5 times the funded amount.
OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties
OPKO Health (NASDAQ: OPK) has expanded its financing relationship with HealthCare Royalty by issuing an additional $125 million in senior secured notes, backed by royalty interests from its mazdutide license with Eli Lilly. These notes mature in 2044, and the agreement caps total payments at 1.5 times the funded amount, allowing OPKO to retain future royalty economics thereafter. This move provides non-dilutive capital and strengthens the company's balance sheet while preserving long-term upside from the mazdutide franchise, which began generating royalty revenue in 2025 from commercialization in China by Innovent Biologics.
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health has expanded its financing relationship with HealthCare Royalty (HCRx), a KKR business, by issuing an additional $125 million in senior secured notes. These notes are backed by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company, maturing in 2044. The transaction provides OPKO with non-dilutive capital, enhances financial flexibility, and preserves long-term royalty upside, as total payments are capped at 1.5 times the funded amount.
OPKO Health Expands Strategic Relationship with HealthCare
OPKO Health has expanded its financing relationship with HealthCare Royalty (HCRx), a KKR business, through a $125 million issuance of senior secured notes. These notes are backed by OPKO’s royalty interests from its mazdutide license agreement with Eli Lilly and Company, maturing in 2044. This transaction provides OPKO with non-dilutive capital and financial flexibility while preserving significant long-term royalty upside from the mazdutide franchise, which is commercialized in China by Innovent Biologics.
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health announced an expanded financing relationship with HealthCare Royalty (a KKR business) through a $125 million senior secured notes issuance. These notes are backed by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company, providing OPKO with non-dilutive capital and financial flexibility while preserving long-term royalty upside. Mazdutide is commercialized in China by Innovent Biologics, and this transaction leverages an emerging royalty stream to strengthen OPKO's balance sheet.
Does OPKO Health’s Sharply Narrowed Q2 Loss Reset the Bull Case for OPKO Health (OPK)?
OPKO Health, Inc. (OPK) reported a significantly narrowed net loss of US$8.42 million in Q2 2026, alongside increased revenue of US$163.58 million, which could signal progress in cost control and operations management. While the company remains unprofitable, this positive development, combined with their 2026 revenue guidance of US$560 million to US$585 million, may influence the investment narrative and future expectations for the stock. Analysts hold varying opinions on OPKO Health's potential, with some projecting a substantial upside and positive earnings by 2029, emphasizing the importance of monitoring future performance against current guidance.
Does OPKO Health’s Sharply Narrowed Q2 Loss Reset the Bull Case for OPKO Health (OPK)?
OPKO Health (OPK) reported a significantly narrowed net loss of US$8.42 million in Q2 2026, down from US$148.44 million the previous year, alongside a modest revenue increase to US$163.58 million. While this progress highlights improved cost control, the company's long-term profitability and sustained funding needs remain key investment considerations. Investors are closely watching upcoming quarters against OPKO's 2026 revenue guidance of US$560 million to US$585 million to assess if this improved performance is a consistent trend towards profitability.
Opko Health | SCHEDULE 13D: Others
This article provides details about a Schedule 13D filing related to Opko Health. Schedule 13D filings are required when a person or group acquires more than 5% of a company's stock, indicating a potentially active investment or influence on the company.
Cocrystal Pharma Secures $5 Million Investment from OPKO Health as Norovirus Program Advances Toward Phase 1b Data
Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health, increasing OPKO's stake in the company. This funding will support Cocrystal's norovirus program, particularly its lead candidate CDI-988, as it advances towards releasing topline data from its Phase 1b clinical trial by late 2026. The investment reflects OPKO's continued confidence in Cocrystal's antiviral research and pipeline.
Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health
Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health through a private placement of 5,474,053 common shares at $0.9134 per share. The biotech company plans to use these proceeds to advance its preclinical and clinical antiviral programs, including its lead norovirus candidate CDI-988, for which topline Phase 1b data is expected by the end of Q4 2026. This investment reinforces OPKO's confidence in Cocrystal's antiviral platform and its development pipeline.
OPKO Buys 5.47M Cocrystal Shares Ahead of Late-2026 Norovirus Data
OPKO Health has made a $5 million private placement in Cocrystal Pharma, purchasing 5,474,053 common shares at $0.9134 per share. This investment aims to support the advancement of Cocrystal's lead norovirus candidate, CDI-988, with topline Phase 1b data anticipated by the end of the fourth quarter of 2026. Both companies emphasized OPKO's long-standing confidence in Cocrystal's antiviral pipeline, though the share issuance will result in equity dilution for existing shareholders.
OPKO Health (OPK) Is Up 14.1% After Narrower Q2 Loss and New 2026 Revenue Guidance – Has The Bull Case Changed?
OPKO Health (OPK) reported a significantly narrower Q2 net loss of US$8.42 million and issued new 2026 revenue guidance of US$560 million to US$585 million, leading to a 14.1% stock increase. The article explores whether this reduced loss and updated guidance change the investment narrative, which has historically been challenged by losses and volatility. Investors are encouraged to assess if the diagnostics segment can achieve breakeven and if the shrinking net loss can be sustained without external financing.
OPKO Health (OPK) Is Up 14.1% After Narrower Q2 Loss and New 2026 Revenue Guidance – Has The Bull Case Changed?
OPKO Health (OPK) reported a narrower Q2 loss and new 2026 revenue guidance, sending its stock up 14.1%. The company's net loss significantly contracted, suggesting a positive shift in its loss profile. Investors will now focus on whether the diagnostics segment can achieve breakeven and if the reduced net loss can be sustained without external financing.
Opko Health, Inc. Revenue Breakdown – NASDAQ:OPK
Opko Health, Inc. (NASDAQ: OPK) generated $606.90 million in revenue last year, with its Diagnostics segment being the top performer at $370.27 million. The United States was the largest geographical contributor, accounting for $436.06 million of the revenue. These figures provide a breakdown of the company's revenue streams by segment and region.
Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
OPKO Health, Inc. recently reported a significant earnings beat, surpassing analyst revenue and statutory EPS forecasts. Following these results, analysts have raised their revenue and EPS estimates for the company's future performance, suggesting a more optimistic outlook. The revised forecasts indicate a positive sentiment among analysts regarding OPKO Health's financial trajectory.
OPKO Health FY2026 EPS Estimate Increased by HC Wainwright
HC Wainwright has increased its FY2026 EPS estimate for OPKO Health to a loss of $0.23 per share from $0.30, while maintaining a "Buy" rating. This upgrade follows OPKO's recent quarterly results, which surpassed expectations with a $0.01-per-share loss against an estimated $0.08 loss and a 4.3% year-over-year revenue increase to $163.58 million. Despite the improved outlook, the consensus analyst rating for OPKO Health remains "Hold" with a price target of $1.55, as shares recently traded at $1.36.
OPKO Health Number of Employees 2026 | Employee Count & Headcount Data
OPKO Health (NASDAQ: OPK) had approximately 2,275 employees worldwide as of March 2026, representing a 13.9% decline from 2023. Despite this decline, the company is actively hiring, with 129 active job postings in 2026, a 71.6% increase from the previous year. The workforce is primarily concentrated in the United States, with Engineering being the largest functional group, and the average salary is $74,367.
OPKO Health (NASDAQ:OPK) Reaches New 52-Week High - Here's Why
OPKO Health (NASDAQ:OPK) shares recently hit a new 52-week high after reporting second-quarter results that significantly beat expectations. The company narrowed its adjusted loss and saw revenue rise 4.3% year over year, leading management to raise its 2026 revenue outlook. Despite these positive developments and pipeline catalysts, OPKO remains unprofitable, and analysts maintain a "Reduce" rating with an average price target of $1.55.
OPK|OPKO Health Inc|Price:1.650|Chg%:+0.410
This article provides a comprehensive stock analysis of OPKO Health Inc (OPK), highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes high institutional ownership and recent "Buy" ratings from analysts, with expectations for the stock price to trend upward in the medium term despite current sideways trading. The analysis details the company's biopharmaceutical and diagnostics segments, key products like Somatrogon and Rayaldee, and assesses its financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk management through TradingKey's proprietary scoring system.
OPKO Health (OPK) VP withholds 53,266 shares for taxes
OPKO Health's Executive VP-Administration, Steven D. Rubin, reported a tax-related share withholding on July 24, 2026. A total of 53,266 shares of common stock, valued at $1.22 per share, were withheld to cover tax obligations stemming from vested restricted stock units. Following this transaction, Rubin directly owns 6,571,966 shares of OPKO Health common stock.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPKO Health reported a narrower-than-expected loss and higher revenues for Q2 2026, driven by strong growth in its Pharmaceuticals segment and exceeding analyst estimates. The company also raised its full-year 2026 revenue guidance. This positive performance is attributed to improved pharmaceutical revenues, including income from a licensing agreement, and a decline in overall costs.
Biopharmaceutical and Diagnostics Stock OPKO Health, Inc. (NASDAQ: OPK) Reaches 52 Week High on Second Quarter News
OPKO Health, Inc. (NASDAQ: OPK) saw its stock reach a new 52-week high after reporting strong second-quarter 2026 financial results and significant progress in its clinical programs. The company posted consolidated revenue of $163.5 million and a narrowed net loss of $8.4 million, with multiple advancements in ModeX and OPKO Biologics' clinical pipeline, including CAR T, tetraspecific antibody, and growth hormone receptor antagonist candidates.
OPKO Health Q2 Earnings Call Highlights
OPKO Health reported a narrower Q2 loss and increased revenue, driven by diagnostics restructuring and a China commercialization agreement. The company ended the quarter with over $300 million in cash and repurchased 9.7 million shares. OPKO also raised its full-year revenue outlook and continues to advance its clinical development programs, including a MASH study and in vivo CAR-T plans.
OPKO Health (NASDAQ:OPK) Shares Gap Up Following Strong Earnings
OPKO Health (NASDAQ:OPK) saw its shares gap up after reporting better-than-expected quarterly earnings, with a loss of $0.01 per share against an anticipated $0.08 loss and revenue of $163.58 million, exceeding estimates. The company also raised its 2026 revenue outlook and plans to advance new antibody programs into clinical studies. Despite the positive financial and pipeline updates, OPKO Health remains unprofitable, leading analysts to maintain a "Reduce" consensus rating with a $1.55 price target.
OPK Looks 17.0% Overvalued on GF Value™
OPKO Health Inc (OPK) is currently valued as 17.0% overvalued based on GuruFocus's GF Value™ at $1.24 per share against an intrinsic value of $1.06, despite beating Q2 revenue expectations. The company, operating in medical diagnostics and research, shows mixed signals with a GF Score™ of 57/100, indicating strong momentum but weak profitability and growth, alongside concerns regarding its financial strength and a negative Altman Z-Score. While institutional guru interest is limited, insider purchases suggest some confidence in its future.
OPKO Health Inc reports results for the quarter ended June 30 - Earnings Summary
OPKO Health Inc has released its financial results for the quarter ended June 30. The article, sourced from Reuters, provides an earnings summary for the company. Readers can access the full report on TradingView.
OPKO Health: Q2 Earnings Snapshot
This article is an earnings snapshot for OPKO Health's Q2 results. However, the content provided is incomplete and does not contain any financial details or specific information regarding their performance.
OPKO Begins Phase 1 Trials in B-Cell Lymphoma, COVID Prevention
OPKO Health reported Q2 2026 revenues of $163.5 million, an increase from the previous year, with a narrowed net loss. The company highlighted significant progress in its clinical programs, including initiating Phase 1 trials for MDX2003 in B-cell lymphoma and MDX2301 for COVID-19 prevention, and expanded its Nicoya agreement for RAYALDEE commercialization in Greater China. OPKO also provided full-year 2026 revenue guidance of $560-$585 million.
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. reported its second-quarter 2026 financial results, showcasing significant progress in its clinical pipeline, particularly with ModeX and OPKO Biologics. The company saw an increase in total consolidated revenues to $163.5 million, up from $156.8 million in 2025, and a reduced net loss of $8.4 million compared to $148.4 million in the prior year. OPKO also provided financial guidance for the third quarter and full year 2026, projecting total revenues between $131-$142 million for Q3 and $560-$585 million for the full year.
OPK|OPKO Health Inc|Price:1.220|Chg%:+0.050
This article provides a detailed financial overview of OPKO Health Inc (OPK), including its stock performance, market capitalization, and key financial indicators. It presents quarterly and annual data for EPS, revenue, net profit, net margin, gross margin, debt-to-assets ratio, and income statement components. The report also highlights the company's latest earnings date, EPS and revenue forecasts, and analyst ratings, alongside FAQs about its financial performance.
OPKO Health, Inc. Revenue Breakdown – DUS:XCY
This article provides a revenue breakdown for OPKO Health, Inc. (DUS:XCY), detailing its top-performing segments and geographical contributions. In the last year, the company generated €516.73 million, with the Diagnostics segment accounting for €315.26 million, and the United States being the largest contributor with €371.27 million.
OPKO Health Inc (OPK) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of OPKO Health Inc (OPK), noting its current valuation score of 7.85 within the Healthcare Providers & Services industry. It details the company's financial metrics including a P/E ratio of -4.48 and highlights that other key valuation data like P/B, P/S, and P/CF have not yet been disclosed by the company.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health, Inc. (OPK) is positioned for growth due to its RAYALDEE product and strategic partnerships, despite a recent stock decline. The company is restructuring its BioReference diagnostics business, expanding its prostate cancer test, and developing new digital platforms. While the pipeline includes numerous early-stage clinical developments and potential for profitability is still dependent on successful execution, the company continues to leverage collaborations and advance its ModeX pipeline.
OPKO Health Sets July 27 Webcast for Results and Guidance
OPKO Health (NASDAQ: OPK) announced it will report its second-quarter 2026 operating and financial results on Monday, July 27, 2026. The company's senior management will host a conference call and webcast at 4:30 p.m. ET to discuss the results, provide a business update, and offer financial guidance. Investors can pre-register for the call or access a webcast via OPKO's Investor Relations website, with replays available until early August 2026.
